NN-429

NN-429 (I-50) potently inhibits purified human HDAC6 with an IC₅₀ of 0.017 μM^[1].
NN-429 inhibits the viability of MV-4-11 acute myeloid leukemia cells with an IC₅₀ of 1.6 μM; it also inhibits the viability of MM.1S multiple myeloma cells with an IC₅₀ of 1.2 μM, but shows no significant toxicity to MRC9 healthy lung fibroblasts^[1].
NN-429 (6 h) selectively inhibits HDAC6 activity in MV-4-11 acute myeloid leukemia cells and MM.1S multiple myeloma cells^[1].
NN-429 induces apoptosis in MV-4-11 acute myeloid leukemia cells in a concentration-dependent manner^[1].
NN-429 potently and selectively inhibits purified human HDAC6 with an IC₅₀ of 3.2 nM^[2].
NN-429 (28.8 nM) binds to the catalytic domain 2 of recombinant zebrafish HDAC6, with an IC₅₀ of 28.8 nM^[2].
NN-429 (0-5 μM; 6 h) selectively binds to HDAC6 in MM.1S multiple myeloma cells and MV4-11 acute myeloid leukemia cells, induces dose-dependent α-tubulin acetylation, and exhibits extremely weak off-target acetylation of histone H3^[2].
NN-429 (72 h) exhibits selective cytotoxicity against human γδ T-cell lymphoma (DERL-2, DERL-7) and NK/T-cell lymphoma (MTA, YT) cell lines, with IC₅₀ values ranging from 0.72 to 2.32 μM, whereas it shows only extremely low activity against cutaneous T-cell lymphoma cells (Myla, IC₅₀ >50 μM)^[2].
NN-429 (0.1-5 μM; 18 h) induces dose-dependent early apoptosis in DERL-2 γδ T-NHL cells^[2].
NN-429 (0.5-5 μM; 24 h) selectively binds to HDAC6 in YT NKTCL cells, induces dose-dependent α-tubulin acetylation, and exhibits extremely weak off-target acetylation of histone H3^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.